Biotechnology and Bioprocess Engineering:BBE

  • 제7권6호
  • /
  • Pages.340-346
  • /
  • 2002
  • /
  • 1226-8372(pISSN)
  • /
  • 1976-3816(eISSN)
한국생물공학회 (The Korean Society for Biotechnology and Bioengineering)
권호 표지

Removal and Inactivation of Hepatitis A Virus during Manufacture of Urokinase from Human Urine

  • Kim, In-Seop (Central Research Center, Green Cross Plasma Derivatives Company) ;
  • Park, Yong-Woon (Central Research Center, Green Cross Plasma Derivatives Company) ;
  • Lee, Sung-Rae (Central Research Center, Green Cross Plasma Derivatives Company) ;
  • Yong Kang (Central Research Center, Green Cross Plasma Derivatives Company) ;
  • Lee, Kyung-Myung (Department of Production, Green Cross Biotech Company) ;
  • Park, Dae-Han (Department of Production, Green Cross Biotech Company) ;
  • Woo, Han-Sang (Central Research Center, Green Cross Plasma Derivatives Company) ;
  • Lee, Soungmin (Central Research Center, Green Cross Plasma Derivatives Company)
  • 발행 : 2002.12.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The purpose of the present study was to examine the efficacy and mechanism of the PAB (para-amino benzamidine) affinity column chromatography, Viresolve NFP virus filtration, pasteurization (60$\^{C}$ heat treatment for 10 h), and lyophilization steps employed in the manufacture of urokinase from human urine as regards the removal and/or inactivation of the hepatitis A virus (HAV). Samples from the relevant stages of the production process were spiked with HAV and subjected to scale-down processes mimicking the manufacture of urokinase Samples were collected at each step, immediately titrated using a 50% tissue culture infectious dose (TCID$\_$50/), and the virus reduction factors evaluated. PAB chromatography was found to be an effective step for removing HAV with a log reduction factor of 3.24. HAV infectivity was rarely detected in the urokinase fraction, while most of the HAV infectivity was recovered in the unbound and wash fractions. HAV was completely removed during the Viresolve NFP filtration with a log reduction factor of $\geq$ 4.60. Pasteurization was also found to be an effective step in inactivating HAV where the titers were reduced from an initial titer of 7.18 log$\_$10/ TCID$\_$50/ to undetectable levels within 10 h of treatment. The log reduction factor achieved during pasteurization was $\geq$ 4.76. Lyophilization revealed the lowest efficacy for inactivating HAV with a log reduction factor of 1.48. The cumulative log reduction factor was $\geq$ 14.08. Accordingly, these results indicate that the production process for urokinase exhibited a sufficient HAV reducing capacity to achieve a high margin of virus safety.

키워드

참고문헌

  1. Drugs v.33 no.Sup.3 Thrombolytic therapy in acute myocardial infarction. A perspective. Sherry, S.
  2. J. Infect. Dis. v.141 Detection of hepatitis A virus in the feces of patients with naturally acquired infections. Coulepis, A. G.;S. A. Locarnini;N. I. Lehmann;I. D. Gust https://doi.org/10.1093/infdis/141.2.151
  3. Balliere Tindal Andrewes’ Viruses of Vertebrates Andrewes, C.
  4. Biologicals v.26 Inactivation kinetics of model and relevant bloodborne viruses by treatment with sodium hydroxide and heat Borovec, S.;C. Broumis;W. Adcock;R. Fang;E. Uren https://doi.org/10.1006/biol.1998.0146
  5. J. Microbiol. v.39 Removal and inactivation of hepatitis A virus during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma. Kim, I. S.;Y. W. Choi;S. R. Lee;M. S. Lee;K. H. Huh;S. Lee
  6. Transfusion v.39 Foundling viruses and transfusion medicine. Mosley, J. W.;J. Rakela https://doi.org/10.1046/j.1537-2995.1999.39101041.x
  7. Note for guidance on virus validation studies: the design, contribution and removal of viruses (CPMP/BWP/268/95). The European Agency for the Evaluation of Medicinal Products;Human Medicines Evaluation Unit.;Committee for Proprietary Medicinal Products (CPMP).
  8. Federal Resister v.63 no.185 Guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; Availability. International Conference on Harmonisation
  9. J. Microbiol. v.38 Solvent/detergent inactivation and chromatographic removal of human immunodeficiency virus during the manufacturing of a high purity antihemophilic factor VIII concentrate. Kim, I. S.;Y. W. Choi;H. S. Woo;C. E. Chang;S. Lee
  10. Biotechnol. Bioprocess Eng. v.6 Removal and inactivation of human immunodeficiency virus (HIV-1) by cold ethanol fractionation and pasteurization during the manufacture of albumin and immunoglobulins from human plasma. Kim, I. S.;H. G. Eo;C. W. Park;C. E. Chang;S. Lee https://doi.org/10.1007/BF02942246
  11. Biotechnol. Bioprocess Eng. v.7 Enhanced virus removal by flocculation and microfiltration. Han, B.;J. O. Carlson;S. M. Powers;S. R. Wickramasinghe https://doi.org/10.1007/BF02935872
  12. J. Microbiol. Biotechnol. v.11 Improvement of virus safety of a human intravenous immunoglobulin by low pH incubation. Kim, I. S.;Y. W. Choi;S. R. Lee;H. B. Cho;H. G. Eo;H. S. Woo;C. E. Chang;S. Lee
  13. Bio. Pharm. Viral clearance strategies for biopharmaceutical safety: Part 1. General considerations. Arahana, H.
  14. J. Microbiol. Biotechnol. v.11 Removal and inactivation of viruses during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma. Kim, I. S.;Y. W. Choi;S. R. Lee;H. S. Woo;S. Lee
  15. Vox Sang. v.67 no.Sup. 1 Removal and inactivation of hepatitis A virus (HAV) during processing of factor VIII concentrates. Hamman, J.;J. Zou;B. Horowitz
  16. J. Med. Virol. v.43 Removal/neutralization of hepatitis A virus during manufacture of high purity, solvent/detergent factor VIII concentrate. Lemon, S. M.;P. C. Murphy;A. Smith;J. Zou;J. Hammon;S. Robinson;B. Horowitz https://doi.org/10.1002/jmv.1890430109
  17. Biotechnol. Appl. Biochem. v.28 Chromatographic removal and heat inactivation of hepatitis A virus during manufacture of human albumin. Adcock, W. L.;A. Macgregor;J. R. Davies;M. Hattarki, D.;A. Anderson;N. H. Goss
  18. Bio. Pharm. Viral clearance strategies for biopharmaceutical safety. Part 2: Filtration for viral clearance. Arahana, H.
  19. Biologicals v.26 Clearance of murine leukaemia virus from monoclonal antibody solutions by a hydrophilic PVDF microporous membrane filter. Aranha-Creado, H.;J. Peterson;P. Y. Huang https://doi.org/10.1006/biol.1998.0130
  20. Biologicals v.24 Nanofiltration of immunoglobulin with 35-nm filters fails to remove substantial amounts of HCV. Eibl, J.;N. Barrett;T. Hammerle;F. Dorner https://doi.org/10.1006/biol.1996.0036
  21. Dev. Biol. Stand. v.99 Virus removal by filtration. Graf, E. G.;E. Jander;A. West;H. Pora;H. Aranha-Creado
  22. Vox Sang. v.75 (2001) Removal and inactivation of viruses during hepatitis B virus, hepatitis C virus and simian virus 40 using a polyvinylidene fluoride membrane filter. Oshima, K. H.;T. T. Evans-strickfaden;A. K. Highsmith https://doi.org/10.1046/j.1423-0410.1998.7530181.x
  23. Biologicals v.24 The use of a microporus polyvinylidene fluoride (PVDF) membrane filter to separate contaminating viral particles from biologically important proteins. Oshima, K. H.;T. T. Evans-strickfaden;A. K. Highsmith;E. W. Ades https://doi.org/10.1006/biol.1996.0018
  24. J. Virol. Methods v.65 Efficient removal of viruses by a novel polyvinylidene fluoride membrane filter. Roberts, P. https://doi.org/10.1016/S0166-0934(96)02163-5
  25. Biologicals v.26 Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration. Troccoli, N.;J. Mclver;A. Losikoff;J. Poiley https://doi.org/10.1006/biol.1998.0164
  26. J. Microbiol. Biotechnol. v.10 Partitioning and inactivation of viruses by cold ethanol fractionation and pasteurization during manufacture of albumin from human plasma. Kim, I. S.;H. G. Eo;C. E. Chang;S. Lee
  27. Curr. Stud. Hematol. Blood Transfus. v.56 Strategies to produce virus-safe blood derivatives. Heimburger, N.;H. E. Karges
  28. Dev. Biol. Stand. v.81 Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurization. Nowak, T.;M. Niedrig;D. Bernhardt;J. Hilfenhaus